[{"uuid": "bdfd94d5-6843-3a2f-87e3-8ef227ae40dd", "title": "EyePoint to Present at Guggenheim SMID Cap Biotech Conference", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/eyepoint-present-guggenheim-smid-cap-120000292.html", "providerPublishTime": 1738238400, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/54.CAHG2kXVlkMCbowV89Q--~B/aD02MDt3PTI5NDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/dd36e9c3ac27380117e5576e26f7cef8", "width": 294, "height": 60, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/ursC04PZoPQkNFvKfzCjOg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/dd36e9c3ac27380117e5576e26f7cef8", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["EYPT"]}, {"uuid": "c8c4bdba-efcb-3d37-bc20-37b847d718ba", "title": "Strong week for EyePoint Pharmaceuticals (NASDAQ:EYPT) shareholders doesn't alleviate pain of one-year loss", "publisher": "Simply Wall St.", "link": "https://finance.yahoo.com/news/strong-week-eyepoint-pharmaceuticals-nasdaq-123554470.html", "providerPublishTime": 1737808554, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/H9sVDVM9mi9ws1HvXhxW7w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316", "width": 1194, "height": 432, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/hG0OCZI55yVVgXDa9Dxy1Q--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["EYPT"]}, {"uuid": "4a1197e8-9a17-3550-a69e-4d7d367ef532", "title": "EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/eyepoint-pharmaceuticals-reports-inducement-grants-120000583.html", "providerPublishTime": 1737028800, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/54.CAHG2kXVlkMCbowV89Q--~B/aD02MDt3PTI5NDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/dd36e9c3ac27380117e5576e26f7cef8", "width": 294, "height": 60, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/ursC04PZoPQkNFvKfzCjOg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/dd36e9c3ac27380117e5576e26f7cef8", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["EYPT"]}, {"uuid": "92794c97-1a42-3c60-be6c-beec40cb1adb", "title": "EyePoint Provides Company Update and Anticipated Development Milestones for 2025", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/eyepoint-provides-company-anticipated-development-120000764.html", "providerPublishTime": 1736769600, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/54.CAHG2kXVlkMCbowV89Q--~B/aD02MDt3PTI5NDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/dd36e9c3ac27380117e5576e26f7cef8", "width": 294, "height": 60, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/ursC04PZoPQkNFvKfzCjOg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/dd36e9c3ac27380117e5576e26f7cef8", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["EYPT"]}, {"uuid": "47ccf4bd-1507-375f-992d-0cb17b260f09", "title": "EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of Directors", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/eyepoint-appoints-renowned-retina-specialist-120000534.html", "providerPublishTime": 1736337600, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/54.CAHG2kXVlkMCbowV89Q--~B/aD02MDt3PTI5NDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/dd36e9c3ac27380117e5576e26f7cef8", "width": 294, "height": 60, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/ursC04PZoPQkNFvKfzCjOg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/dd36e9c3ac27380117e5576e26f7cef8", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["EYPT"]}, {"uuid": "874ac3b6-d8a4-3c72-ae76-e1991a9a6c75", "title": "Citigroup Initiates EyePoint Pharmaceuticals at Buy With $33 Price Target", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/citigroup-initiates-eyepoint-pharmaceuticals-buy-132236187.html", "providerPublishTime": 1736256156, "type": "STORY", "relatedTickers": ["EYPT"]}, {"uuid": "1c17967d-95ca-39a7-9a9d-ceeaf5d9832b", "title": "EyePoint reports inducement grants under NASDAQ listing rule", "publisher": "TipRanks", "link": "https://finance.yahoo.com/news/eyepoint-reports-inducement-grants-under-122529566.html", "providerPublishTime": 1734438329, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/JAkd0u.p7aqm9cNkwT3ICg--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/c7cc0ee97ba22ee31ce2f6fcf51d1f91", "width": 192, "height": 192, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/noN3BfKp3iIZZgFc7RdX4A--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/tipranks_452/c7cc0ee97ba22ee31ce2f6fcf51d1f91", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["EYPT"]}, {"uuid": "a2c375e7-d206-3707-9d15-17c6d7d56c15", "title": "EyePoint doses first patient in second Phase 3 LUCIA clinical trial", "publisher": "TipRanks", "link": "https://finance.yahoo.com/news/eyepoint-doses-first-patient-second-120644066.html", "providerPublishTime": 1733400404, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/.2OcvspZzvCzzeMPm.N5LA--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/373719bd4f9106065622fdb013c92607", "width": 192, "height": 192, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/mgr3GIr91HdofkXwyQ9rdA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/tipranks_452/373719bd4f9106065622fdb013c92607", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["EYPT"]}, {"uuid": "31ae4de9-cdc7-3b3b-8c08-28036ce1f90f", "title": "EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Lags Revenue Estimates", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/eyepoint-pharmaceuticals-eypt-reports-q3-133506618.html", "providerPublishTime": 1730986506, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/OL7xfT5pzuzwP2wxb1pcSw--~B/aD02MjU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/7ea641b46fe75c0a913349e5e610d6a2", "width": 900, "height": 625, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/b9rAc1dD4ZmWarIFuNIcGw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/7ea641b46fe75c0a913349e5e610d6a2", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["EYPT"]}, {"uuid": "c6e34c6f-edfe-32f4-90fe-95e8b6c0d51e", "title": "Wall Street Analysts See a 175.07% Upside in EyePoint Pharmaceuticals (EYPT): Can the Stock Really Move This High?", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/wall-street-analysts-see-175-145510736.html", "providerPublishTime": 1731509710, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/AwCmIhR0z9Bg4cEkwuNQjw--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/8442d24e11d454aa89061259a9714d43", "width": 900, "height": 601, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/n4.AbgyuCxTPgpWcYEizKw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/8442d24e11d454aa89061259a9714d43", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["EYPT"]}, {"uuid": "8373a9d6-2297-372b-8aff-7ac7f16a4d52", "title": "EyePoint to Present at the 43rd Annual J.P. Morgan Healthcare Conference", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/eyepoint-present-43rd-annual-j-120000369.html", "providerPublishTime": 1734436800, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/54.CAHG2kXVlkMCbowV89Q--~B/aD02MDt3PTI5NDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/dd36e9c3ac27380117e5576e26f7cef8", "width": 294, "height": 60, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/ursC04PZoPQkNFvKfzCjOg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/dd36e9c3ac27380117e5576e26f7cef8", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["EYPT"]}, {"uuid": "3057094f-09bc-3240-b0bc-8f35745c3c8a", "title": "EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU\u2122 for the Treatment of Wet Age-Related Macular Degeneration", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/eyepoint-announces-first-patient-dosed-120000607.html", "providerPublishTime": 1733313600, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/54.CAHG2kXVlkMCbowV89Q--~B/aD02MDt3PTI5NDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/dd36e9c3ac27380117e5576e26f7cef8", "width": 294, "height": 60, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/ursC04PZoPQkNFvKfzCjOg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/dd36e9c3ac27380117e5576e26f7cef8", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["EYPT"]}, {"uuid": "b5cea704-f84a-3aee-bfd9-52d9c2431e1f", "title": "EyePoint Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags", "publisher": "Simply Wall St.", "link": "https://finance.yahoo.com/news/eyepoint-pharmaceuticals-third-quarter-2024-130442891.html", "providerPublishTime": 1731157482, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c", "width": 945, "height": 636, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/NamfX5LEtyScIu4YmRG2hg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["EYPT"]}, {"uuid": "0d75beeb-d84e-3b02-a81b-558d38ecb066", "title": "EyePoint price target lowered to $33 from $38 at Baird", "publisher": "TipRanks", "link": "https://finance.yahoo.com/news/eyepoint-price-target-lowered-33-114545856.html", "providerPublishTime": 1731411945, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/CelDdPDqWVkcG2SiBC__kg--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/c4f6c07e08d4829fbea65fa26099a197", "width": 192, "height": 192, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/JPH2pCpc9DwVOqszBsURww--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/tipranks_452/c4f6c07e08d4829fbea65fa26099a197", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["EYPT"]}, {"uuid": "87a30b0f-a6f8-3949-9380-0a1773b54aa8", "title": "EyePoint Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Developments", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/eyepoint-pharmaceuticals-reports-third-quarter-120000114.html", "providerPublishTime": 1730980800, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/54.CAHG2kXVlkMCbowV89Q--~B/aD02MDt3PTI5NDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/dd36e9c3ac27380117e5576e26f7cef8", "width": 294, "height": 60, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/ursC04PZoPQkNFvKfzCjOg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/dd36e9c3ac27380117e5576e26f7cef8", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["EYPT"]}, {"uuid": "57da4daf-a359-3254-b30b-8eb257423003", "title": "EyePoint Pharmaceuticals: Q3 Earnings Snapshot", "publisher": "Associated Press Finance", "link": "https://finance.yahoo.com/news/eyepoint-pharmaceuticals-q3-earnings-snapshot-123722471.html", "providerPublishTime": 1730983042, "type": "STORY", "relatedTickers": ["EYPT"]}]